arrow
Y

Yago Nieto

the university of texas m d anderson cancer center
H指数:54
被引数:1.4万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Daratumumab ± pomalidomide maintenance after salvage autologous transplantation in relapsed multiple myeloma: a phase 2 study

在复发多发性骨髓瘤中,自体移植后使用达鲁单抗±泊马利度胺进行维持治疗:一项2期研究

2026-09-260
OAAI
Carfilzomib, lenalidomide, and dexamethasone (KRd) versus bortezomib, lenalidomide, and dexamethasone (VRd) induction prior to autologous haematopoietic stem cell transplant/transplantation in newly diagnosed multiple myeloma

卡非佐米、来那度胺和地塞米松(KRd)与硼替佐米、来那度胺和地塞米松(VRd)在自体造血干细胞移植/移植前诱导治疗新诊断多发性骨髓瘤的比较

2026-08-200
PRE
Donor-specific HLA mismatch: haploidentical versus 7/8 mismatched unrelated donor hematopoietic cell transplantation with PTCy

供者特异性HLA错配:单倍型与7/8位点错配无关供者造血干细胞移植联合PTCy

2026-06-170
PRE
Randomized trial of two fractionation schedules of myeloablative busulfan with fludarabine and cladribine in AML or MDS

随机对照试验:评估两种分次治疗方案下,在AML或MDS患者中使用大剂量白消安联合氟达拉滨和克拉屈滨的骨髓清除效果

2026-06-120
PRE
D-VRD induction and autologous transplant in patients ≥70 years

D-VRD诱导和自体移植在≥70岁患者中的应用

2026-06-050
OAAI
Results of delayed or salvage autologous hematopoietic stem cell transplantation for multiple myeloma

延迟或挽救性自体造血干细胞移植治疗多发性骨髓瘤的结果

2025-12-050
PRE
Hematopoietic Cell Transplantation, Version 3.2025

造血细胞移植,版本 3.2025

2025-10-011
PRE
CD19 CAR T-Cell Therapy for Primary Mediastinal Large B-Cell Lymphoma: A CIBMTR Analysis

CD19 CAR T细胞疗法治疗原发性纵隔大B细胞淋巴瘤:一项CIBMTR分析

2025-08-110
PRE
Outcomes of Patients with Multiple Myeloma with deletion 1p Following Autologous Stem Cell Transplant

多发性骨髓瘤患者伴有1p缺失行自体干细胞移植后的结局

2025-08-050
PRE
Author Correction: Allogeneic NK cells with a bispecific innate cell engager in refractory relapsed lymphoma: a phase 1 trial

作者更正: 同种异体NK细胞与双特异性先天细胞衔接器治疗难治性复发性淋巴瘤: 1期试验

2025-06-260
PRE
Outcomes of Multiple Myeloma Patients With Prior Solid Tumors Undergoing Autologous Transplantation

多发性骨髓瘤患者既往有实体瘤病史行自体移植的结局

2025-05-160
PRE
Real-World Outcomes of Upfront Autologous Hematopoietic Stem Cell Transplantation in Patients With Newly Diagnosed Multiple Myeloma With Deletion 17p
2025-01-010
PRE
Second Line Treatment in Patients with Multiple Myeloma Progressing after Bortezomib, Lenalidomide, Dexamethasone Induction, Autologous Transplant and Lenalidomide Maintenance

二线治疗在经硼替佐米、来那度胺、地塞米松诱导,自体移植和来那度胺维持治疗后进展的多发性骨髓瘤患者中的应用

BLOOD
IF23.1
2024-11-050
PRE
Conditioning with Busulfan plus Melphalan Versus Single-Agent Melphalan for Patients with Multiple Myeloma Receiving Autologous Stem Cell Transplantation: A Propensity Score-Matched Analysis

以白消安联合美法仑与单药美法仑预处理,用于接受自体干细胞移植的多发性骨髓瘤患者的倾向性评分匹配分析

BLOOD
IF23.1
2024-11-050
PRE
Outcomes after Allogeneic Stem-Cell Transplant in Patients with High-Risk Large-Cell Transformation of Mycosis Fungoides (MF-LCT)

异基因干细胞移植后高危蕈样肉芽肿大细胞转化(MF-LCT)患者的结局

BLOOD
IF23.1
2024-11-050
PRE
Myeloablative Fractionated Busulfan, Fludarabine, Cladribine, Thiotepa and Venetoclax (Cladillac) Conditioning Regimen for Very High-Risk AML/MDS: A Phase 2 Trial

大剂量分次马利兰、氟达拉滨、克拉屈滨、替莫唑胺和维奈克拉(Cladillac)预处理方案用于极高危AML/MDS:一项Ⅱ期临床试验

BLOOD
IF23.1
2024-11-050
PRE
Optimal infused CD34+ cell dose in multiple myeloma patients undergoing upfront autologous hematopoietic stem cell transplantation
2024-10-310
OAAI
Trends in Outcomes After Upfront Autologous Transplant for Multiple Myeloma Over Three Decades
2024-08-010
PRE